Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.23
-5.88 (-2.80%)
AAPL  266.60
+2.02 (0.76%)
AMD  194.97
-5.18 (-2.59%)
BAC  51.40
-1.66 (-3.13%)
GOOG  310.60
-4.30 (-1.37%)
META  637.70
-17.96 (-2.74%)
MSFT  384.02
-13.21 (-3.33%)
NVDA  190.48
+0.66 (0.35%)
ORCL  139.86
-8.22 (-5.55%)
TSLA  395.30
-16.52 (-4.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.